India's Cipla has been aggressive about taking aim at Western meds it thinks are too expensive for the Indian market, sometimes targeting those that have seen their patents pushed aside by compulsory licenses. But drugmaker Merck has a new deal with Cipla that might help it sidestep that issue.
The FDA handed Gilead Sciences an approval for its four-in-one HIV drug Quad, extending its blockbuster franchise with a new drug that is expected to find a quick uptake among patients. Next step: Pricing the drug, which could trigger a backlash among payers and patients.
Merck ($MRK) became the sixth drug company to provide new discounts on AIDS treatments for cash-strapped state drug-assistance programs, or ADAPs. The company is cutting the price on Isentress
Good news for Merck's (NYSE: MRK) HIV drug franchise. The company's Isentress drug fought off the virus as well as older drugs did, when used as start-up therapy in combination with Abbott
The largest HIV/AIDS healthcare provider has banned Merck's sales reps from its clinics, saying that the company has overpriced its drug Isentress. AIDS Healthcare Foundation has been protesting the
Merck is garnering some goodwill in the AIDS community with price-freezes and discounts on its HIV-fighting drugs. First, Merck agreed to keep the new,
> The FDA has approved Merck's Isentress for HIV. This is a new type of drug, which prevents HIV from inserting its DNA into human DNA, stunting its ability to infect cells.
An FDA expert panel has provided an important endorsement for Merck's experimental AIDS drug Isentress. The twice-a-day pill is the first in a new class of AIDS drugs. If fully approved by the